Your fibromyalgia is real. Your genes may be why women are hit harder.

COMT (catechol-O-methyltransferase) is an enzyme that breaks down stress hormones and neurotransmitters. When it’s working normally, it clears adrenaline, dopamine, and norepinephrine from your system within minutes of a stressor. This keeps your nervous system calm and your pain threshold normal.

The Val158Met variant slows this clearance. Roughly 25% of people with European ancestry are homozygous for the slow version. What that means: your stress hormones stay elevated longer, keeping your nervous system in a heightened pain state even after the threat is gone. Your baseline cortisol and adrenaline stay higher. Your pain receptors fire more easily. The effect is especially pronounced in women because estrogen reduces COMT activity further, compounding the problem.

You might describe this as hypervigilance in your nervous system. You startle easily. You can’t relax. Your whole body feels on edge. A minor physical stimulus (a tight waistband, a hug, sleeping in an awkward position) triggers pain that seems disproportionate. That’s your slow COMT keeping your nervous system locked in fight-or-flight mode.

SLC6A4 encodes the serotonin transporter, the protein that recycles serotonin out of the space between neurons so it can be reused. When this recycling works efficiently, serotonin stays available where it’s needed to dampen pain signals. When it doesn’t, serotonin gets cleared too quickly, leaving you depleted.

The short allele variant of the 5-HTTLPR region is carried by roughly 40% of the population. People with one or two short alleles have reduced serotonin reuptake and lower serotonin availability in pain-processing brain regions. This directly lowers your pain threshold and weakens your emotional resilience to stress. Women with this variant are at higher fibromyalgia risk because estrogen can amplify the effect.

You likely notice this as a combination of pain and low mood. Your pain feels worse on days when you’re anxious or depressed. You have a lower tolerance for frustration or setbacks. Pain from one body region can spread to others because your central pain-inhibition system is weak. You might have tried SSRIs (serotonin reuptake inhibitors) with mixed results, because these drugs work by artificially maintaining serotonin in the synapse, bypassing the transporter entirely.

MTHFR is the enzyme that converts folate into its active form (methylfolate), which your body then uses to synthesize serotonin, dopamine, and norepinephrine. It’s also crucial for controlling inflammation and homocysteine levels. When MTHFR works normally, you convert dietary folate into neurotransmitters efficiently. When it doesn’t, you become functionally folate-deficient even if you’re eating plenty of leafy greens.

The C677T variant is carried by roughly 40% of people with European ancestry and reduces enzyme efficiency by 40-70%. The consequence: you cannot synthesize adequate serotonin and dopamine for pain inhibition, even if you’re eating a perfect diet. Your homocysteine also rises, which directly increases pain sensitivity and inflammation. The effect is worse in women during certain phases of the menstrual cycle because hormone changes affect folate metabolism.

You might notice this as fatigue accompanying your pain. Your brain feels foggy. You’ve tried increasing folate intake but nothing changed because your body can’t convert regular folate into the usable form. Your pain flares are often accompanied by low mood. Your body seems to require more sleep than others. Standard bloodwork might show normal folate levels, but your cells are still depleted.

BDNF (brain-derived neurotrophic factor) is a growth factor that maintains existing neurons and encourages growth of new ones. In the context of pain, BDNF controls how central sensitization develops. When BDNF is working normally, your nervous system can repair itself after injury and learn to suppress exaggerated pain signals. When BDNF is reduced, central sensitization becomes entrenched.

The Val66Met variant is carried by roughly 30% of the population and reduces BDNF secretion, impairing your nervous system’s ability to recover from pain sensitization. This means chronic pain becomes harder to reverse. Therapy and rehabilitation are less effective. Your nervous system stays locked in hypersensitivity mode. Women with the Met allele have worse fibromyalgia outcomes and higher pain progression rates.

You might notice this as pain that started after an injury or illness but never fully resolved. Physical therapy helped initially but then plateaued. Your nervous system seems “stuck” in pain mode. You have difficulty with proprioception (knowing where your body is in space). Your exercise tolerance is very low and slow to improve. Learning-based pain management (like cognitive behavioral therapy) is harder for you because your nervous system can’t form new pain-suppression pathways as easily.

OPRM1 encodes the mu-opioid receptor, which sits on pain-sensing neurons and blocks pain signals when activated by endogenous opioids (endorphins and enkephalins your body produces naturally). When these receptors are sensitive, small amounts of natural opioid production create powerful pain relief. When they’re insensitive, you’re functionally opioid-depleted even if your body is producing normal amounts.

The A118G variant (G allele) is carried by roughly 10-15% of people with European ancestry and up to 40% of people with East Asian ancestry. This variant reduces receptor sensitivity to endogenous opioids, leaving you with weaker natural pain-relief capacity. You literally have a lower biological pain ceiling. Women with this variant have worse fibromyalgia outcomes and higher opioid requirements if they ever need pain medication.

You might notice this as a feeling that nothing works for your pain. You’ve tried multiple pain medications with disappointing results. You don’t get the relief others seem to get from the same dose. Your body seems fundamentally less responsive to natural stress-relief activities (exercise, massage, pleasurable experiences) that should trigger endorphin release. You might be labeled opioid-resistant or difficult to treat.

TRPV1 (transient receptor potential vanilloid 1) is a pain receptor on nerve endings that responds to heat, pressure, and chemical irritants. When TRPV1 is functioning normally, it fires only in response to genuine threats (extreme heat, strong pressure, tissue damage). When variants affect TRPV1, these receptors become hypersensitive and fire in response to normal stimuli.

TRPV1 variants affect receptor sensitivity, and roughly 25-30% of the population carries a gain-of-function variant that lowers your pain threshold and makes you hypersensitive to heat, pressure, and chemical irritants. Your skin literally feels more pain from normal touch. Warm environments (showers, hot weather) can trigger widespread pain. Light pressure (tight clothing, bed sheets) causes discomfort. Women are disproportionately affected by TRPV1 variants, possibly because estrogen amplifies TRPV1 signaling.

You might describe this as allodynia: pain from normally non-painful stimuli. You can’t wear tight pants or sweaters. Showers have to be lukewarm. Being touched, even gently, can hurt. Heat and humidity make your pain worse. Your pain is often described as burning or scalding rather than aching. You’re sensitive to environmental chemicals and scents.